SCHEMBL4706512

SCHEMBL4706512

CCn1nc(-c2ccccc2)c(C(C)=O)c(Nc2cccc(OC)c2)c1=O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 1/20 0.67
ACHE P22303 1/20 0.46
BACE1 P56817 1/20 0.46
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
USP2 O75604 2/20 0.45
LMNA P02545 2/20 0.45
CYP1A2 P05177 2/20 0.45
CASP1 P29466 2/20 0.45
CASP7 P55210 2/20 0.45
ALDH1A1 P00352 1/20 0.45
ADRA1D P25100 3/20 0.45
ADRA1A P35348 3/20 0.45
ADRA1B P35368 3/20 0.45
HTR1A P08908 2/20 0.45
POLB P06746 1/20 0.44
TSHR P16473 2/20 0.44
GFER P55789 1/20 0.44
TRPV1 Q8NER1 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1652526 0.92 PDE4B (0.57) PDE4BMEN1KMT2ALMNAALDH1A1
SCHEMBL4705575 0.92 PDE4B (0.70) PDE4BACHEBACE1ADRA1DADRA1A
SCHEMBL4707074 0.91 PDE4B (0.66) PDE4BMEN1KMT2ALMNAALDH1A1
SCHEMBL4705624 0.90 PDE4B (0.64) PDE4BLMNAALDH1A1ADRA1DADRA1A
SCHEMBL4705728 0.89 PDE4B (0.77) PDE4BACHEBACE1ADRA1DADRA1A
SCHEMBL4706634 0.89 PDE4B (0.63) PDE4BSMN1; SMN2
SCHEMBL3022617 0.89 PDE4B (0.65) PDE4BACHEBACE1ADRA1DADRA1A
SCHEMBL4708723 0.88 PDE4B (0.53) PDE4BMEN1KMT2AUSP2LMNA
SCHEMBL3037356 0.88 PDE4B (0.52) PDE4BMEN1KMT2APOLBTSHR
SCHEMBL4708040 0.88 PDE4B (0.72) PDE4BSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7459453-B2 Pyridazin-3(2H)-one derivatives as PDE4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2008-12-02 US claimed
US-20060052379-A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2006-03-09 US claimed
US-7459453-B2 Pyridazin-3(2H)-one derivatives as PDE4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2008-12-02 US disclosed
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS DAL PIAZ VITTORIO 2008-10-30 US disclosed
US-20060052379-A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2006-03-09 US disclosed
EP-1503992-A1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE4 INHIBITORS Almirall Prodesfarma, S.A. (ES) 2005-02-09 EP disclosed
WO-2003097613-A1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE4 INHIBITORS ALMIRALL PRODESFARMA SA (ES) 2003-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS PDE4A, PDE3A, PDE4B PDE4B 3/4885ACHE 51/4885BACE1 1757/4885
US-20060052379-A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors PDE4A, PDE3A, PDE4B PDE4B 3/4885ACHE 51/4885BACE1 1757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.